
US FDA approves Gilead’s twice-yearly injection for HIV prevention
By Deena Beasley and Julie Steenhuysen (Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. Gilead said the drug will be sold under the brand name Yeztugo. Investors and AIDS activists had been eagerly awaiting the regulatory decision for a…